BGPT: Paper Review: In vitro effect of visfatin on endocrine functions of the porcine corpus luteum

Explore by Goal

Quick Explanation Copied

Visfatin (NAMPT) is a phase-dependent luteal regulator in pigs

In primary porcine luteal cells, visfatin/NAMPT modulates steroid output (P4, E2) and prostaglandins (PGE2, PGF2α) in a cycle-stage–dependent manner, and the authors link these effects to NAMPT enzymatic activity (via FK866) plus INSR signaling and ERK/AKT/AMPK pathways using pharmacological inhibitors.

Long Explanation

Paper Review (Science-focused, skeptical, evidence-based)

“In vitro effect of visfatin on endocrine functions of the porcine corpus luteum” • Scientific Reports (2024) • DOI: 10.1038/s41598-024-65102-4

What the study set out to test

The authors aimed to determine how visfatin/NAMPT affects luteal endocrine function in pigs by measuring: (i) steroid secretion (progesterone P4, estradiol E2), (ii) prostaglandin secretion (PGE2, PGF2α), (iii) transcriptional and translational abundance of steroidogenic markers (STAR, CYP11A1, HSD3B, CYP19A1) and prostaglandin receptors (PTGER2, PTGFR), and (iv) phosphorylation/activation in signaling modules (INSR, ERK1/2, AKT, AMPK). They also tested mechanistic dependence using NAMPT inhibition (FK866) and inhibitors of INSR/kinases.

Study design (model, dosing, controls)

Model: primary porcine luteal cell cultures from corpus luteum (CL) at cycle phases confirmed by ovarian morphology: early (days 2–3), mid (days 10–12), late (days 14–16).
Replicates/sampling: six independent in vitro cultures; n=6 per group per experiment; each in vitro culture uses CLs from 5–7 pigs.
Treatments: visfatin at 1, 10, 100 ng/mL ± LH (100 ng/mL) and/or INS (10 ng/mL).
Mechanistic probes: FK866 (NAMPT enzymatic inhibitor, 10 nM) used to test NAMPT enzymatic contribution. Inhibitors used for signaling involvement: S961 (INSR, 1 µM), LY294002 (AKT/PI3K axis, 20 µM), U0126 (ERK/MAPK, 10 µM), and dorsomorphin (AMPK, 10 µM).
Readouts: P4 by RIA, E2 by ELISA, prostaglandins by ELISA, mRNA by TaqMan qPCR (2^-ΔΔCt) normalized to PPIA, protein/phosphoprotein by Western blot and/or phospho-ELISA for INSR.

Core results (phase-dependent endocrine modulation)

1) Progesterone (P4) secretion

The authors report that visfatin effects on P4 depend strongly on estrous-cycle phase: on days 2–3 and 14–16 visfatin downregulated P4, whereas on days 10–12 visfatin increased P4. Visfatin also interacted with LH and INS conditions (including additive suppression/stimulation patterns depending on phase and dose).

2) Estradiol (E2) secretion

The authors report visfatin increased E2 secretion on days 2–3, with more nuanced effects on days 10–12 (dose-dependent: stimulation at 10 ng/mL, inhibition at 1 ng/mL in the reported direction) and largely limited or context-specific effects on days 14–16 (including increases when combined with INS). FK866 generally abolished basal visfatin effects on E2 and modulated hormone-combination responses.

3) Prostaglandins (PGE2, PGF2α)

Visfatin increased PGE2 secretion on days 2–3 and 10–12 but had no effect on days 14–16. For PGF2α, visfatin reduced PGF2α on days 14–16 but had minimal/no effect in earlier phases. FK866 often abolished visfatin’s PGE2 effects in early/mid luteal phases and altered PGF2α directions (including an FK866-only rise early in the luteal phase and a decrease later).

Mechanistic thread (NAMPT enzymatic contribution + signaling dependence)

NAMPT activity (FK866): FK866 disrupted many, but not all, visfatin-driven changes—supporting that at least a subset of visfatin effects requires NAMPT enzymatic activity, while other actions likely involve additional (NAMPT-independent) mechanisms or receptor-mediated signaling not fully blocked by FK866 under all conditions.

Receptor signaling & kinase modules: The authors report that visfatin activates/changes phosphorylation states in INSR, ERK1/2, AKT, and AMPK, with time-course measurements using a single visfatin dose (10 ng/mL) across multiple minutes. They further support causality by showing that INSR and/or kinase pathway inhibition blocks visfatin-stimulated steroid and prostaglandin secretion in their inhibitor experiment design.

Mechanism map (as a testable logic graph)

visfatin → (i) NAMPT enzymatic activity (FK866-sensitive subset) + (ii) cell signaling → INSR/ERK/AKT/AMPK changes → (a) steroidogenic gene/protein modulation → P4/E2 secretion changes (phase-dependent) + (b) prostaglandin receptor regulation → PGE2/PGF2α secretion changes (phase-dependent).

Skeptical critique (what’s strong vs what’s uncertain)

Strengths

Cycle-stage design: measuring early/mid/late luteal phase strengthens biological plausibility for “phase-dependent” regulation (rather than a single snapshot).
Multi-level readouts: secretion endpoints plus mRNA/protein endpoints for steroidogenic/prostaglandin receptor machinery; and pathway activation plus inhibitor studies to connect correlations to causality (within in vitro constraints).

Key uncertainties / potential biases

Pharmacological specificity: inhibitor molecules (S961, LY294002, U0126, dorsomorphin, FK866) can have off-target actions; the study uses them as mechanistic probes, so inhibitor phenotypes are evidence for pathway involvement but not definitive identification of direct molecular targets.
INR phosphorylation paradox/complexity: the reported time-course shows decreased phospho-INSR after visfatin treatment (at 10 ng/mL), yet the inhibitor of INSR signaling abolishes visfatin actions; this implies that the “direction” of phospho-INSR may not map simply onto pathway activation or may reflect feedback/desensitization. The paper addresses this conceptually, but it introduces interpretive complexity that should be treated skeptically.
mRNA–protein decoupling: prostaglandin receptor changes are described as opposite between transcript and protein in some cases (e.g., PTGER2 mRNA up but protein down; PTGFR mRNA down but protein up). That can reflect translational regulation, protein stability, receptor internalization/desensitization, or ligand-driven effects. These are plausible, but the paper’s evidence is observational; the mechanistic “why” remains partly underdetermined by the presented readouts.
In vitro extrapolation: luteal cells in culture may not reproduce in vivo ovarian microenvironment (stromal/immune/trophoblast signaling, local prostaglandin gradients, vascular support). The study claims regulatory relevance for CL physiology in livestock, but in vitro findings require in vivo validation.

Related context from the authors’ broader visfatin axis work (triangulation)

This paper builds on prior porcine reproductive-axis evidence: the same research line reported visfatin/NAMPT expression and secretion regulation in the porcine pituitary across the estrous cycle, including in vitro regulation of visfatin secretion from anterior pituitary cells under hormonal cues. That supports the plausibility of an “endocrine-axis adipokine” integration, though it does not substitute for direct in vivo CL functional validation.

What information would most likely disprove or change the conclusion?

Direct receptor mechanism proof: demonstrating that visfatin actions in luteal cells persist despite INSR pathway blockade (or disappear when an alternative putative receptor is blocked) under the same culture conditions would revise the proposed INSR-centered mechanism.
In vivo outcome linkage: if phase-dependent visfatin perturbation in vivo fails to yield corresponding changes in CL hormone output (P4/E2) and prostaglandin profile, the regulatory interpretation would be weakened. (This is an in-principle disproof criterion; it requires experiments not included in the paper.)

Author reviews on BGPT

Feedback:

Updated: March 23, 2026